Furthermore, clinical trials have demonstrated that low doses of IL-2 are safe and selectively promote thymus-derived Treg cells, thereby demonstrating significant clinical efficacy on active and refractory SLE by enhancing the treatment population (Raeber et al., 2024).The variability in clinical response in different patient subgroups may be attributed to differences in Treg cell deficiency or the role Tregs play in disease development. The gene discussed is IL2; the disease is systemic lupus erythematosus.